In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (PFE 0.47%) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.